Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics

From: Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

 Patients (N = 27)
Age55 (36–76)
ECOG performance status
 08 (30%)
 115 (56%)
 24 (15%)
 Median BMI (range)30 (19–48)
Race/ethnicity
 White18 (67%)
 Asian/Pacific Islander3 (11%)
 Black2 (7%)
 Unknown4 (15%)
 Non-Hispanic18 (67%)
 Hispanic9 (33%)
Initial tumor stage
 I3 (11%)
 II14 (52%)
 III6 (22%)
 IV4 (15%)
Lines of chemo for metastases
 0–112 (44%)
 ≥ 215 (56%)
Sites of metastases
 Distant lymph nodes18 (67%)
 Lung15 (56%)
 Distant skin/subcutaneous tissue11 (41%)
 Bone11 (41%)
 Liver10 (37%)
 Pleura9 (33%)
 Brain2 (7%)
 Others*5 (19%)
  1. *Others are the latissimus dorsi muscle, adrenal glands, ovary, and contralateral breast